S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Cansortium Stock Forecast, Price & News

-0.01 (-1.47%)
(As of 12/3/2021 03:58 PM ET)
Today's Range
50-Day Range
52-Week Range
81,199 shs
Average Volume
270,535 shs
Market Capitalization
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CNTMF News and Ratings via Email

Sign-up to receive the latest news and ratings for Cansortium and its competitors with MarketBeat's FREE daily newsletter.

Cansortium logo

About Cansortium

Cansortium, Inc. engages in the production and sale of medical cannabis. The firm focuses on oil extracted and derived products for use by medical patients. Its objective is to invest in and develop multiple jurisdictions for the vertical integrated approach for the sale and distribution of processed cannabis oil in medical use frameworks. The company was founded by Jose Jaiver Hidalgo and Henry Batievsky on August 31, 2018 and is headquartered in Miami, FL.


Cansortium Reports Third Quarter 2021 Financial Results
November 30, 2021 |  finance.yahoo.com
Cansortium earnings: here's what to expect
November 29, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Drug Manufacturers - Specialty & Generic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Not Optionable


Overall MarketRank

1.47 out of 5 stars

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Cansortium (OTCMKTS:CNTMF) Frequently Asked Questions

Is Cansortium a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cansortium in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cansortium stock.
View analyst ratings for Cansortium
or view top-rated stocks.

How has Cansortium's stock price been impacted by COVID-19?

Cansortium's stock was trading at $0.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CNTMF shares have increased by 234.1% and is now trading at $0.7350.
View which stocks have been most impacted by COVID-19

Are investors shorting Cansortium?

Cansortium saw a decline in short interest during the month of October. As of October 29th, there was short interest totaling 23,500 shares, a decline of 66.0% from the October 14th total of 69,100 shares. Based on an average daily trading volume, of 621,500 shares, the days-to-cover ratio is currently 0.0 days.
View Cansortium's Short Interest

What price target have analysts set for CNTMF?

1 brokers have issued twelve-month price objectives for Cansortium's shares. Their forecasts range from $1.20 to $1.20. On average, they expect Cansortium's stock price to reach $1.20 in the next twelve months. This suggests a possible upside of 63.3% from the stock's current price.
View analysts' price targets for Cansortium
or view top-rated stocks among Wall Street analysts.

Who are Cansortium's key executives?

Cansortium's management team includes the following people:
  • Robert Beasley, Chief Executive Officer & Director
  • Samantha Senne, Executive Vice President-Operations
  • Patricia Fonseca, Chief Financial Officer
  • Henry Batievsky, Chief Production Officer
  • Natalia Velasco, Chief People Officer

What is Cansortium's stock symbol?

Cansortium trades on the OTCMKTS under the ticker symbol "CNTMF."

How do I buy shares of Cansortium?

Shares of CNTMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cansortium's stock price today?

One share of CNTMF stock can currently be purchased for approximately $0.74.

What is Cansortium's official website?

The official website for Cansortium is www.cansortium.com.

Where are Cansortium's headquarters?

Cansortium is headquartered at 82 NE 26th Street, Miami, FL 33137.

How can I contact Cansortium?

Cansortium's mailing address is 82 NE 26th Street, Miami, FL 33137. The company can be reached via phone at (305) 902-2720.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.